Effectiveness of ustekinumab in postoperative Crohn's disease management: Evidence from a Chinese multicenter cohort

doi:10.3748/wjg.v32.i16.116781

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 16

This Article

(31)

(101)

(0)

(24)

(1)

(1041)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Apr 28, 2026; 32(16): 116781
Published online Apr 28, 2026. doi: 10.3748/wjg.v32.i16.116781

Full Size Figure Download Figure

Figure 1 Timing of ustekinumab initiation after surgery by treatment line. A: The distribution highlights the significantly shorter median time from surgery to ustekinumab (UST) initiation in the first-line treatment group compared to that of the second-line group; B: Bar chart showing the proportion of patients receiving early (≤ 6 months) vs late (> 6 months) UST initiation after intestinal resection, stratified by the treatment line (first-line vs second-line UST). UST: Ustekinumab.

Citation: Ma XZ, Han XZ, Zhang WY, Tian F, Zhou XC, Zhou LY, Teng YS, Lei L, Sheng JQ, Jin P, Zhao XM, Jia Y. Effectiveness of ustekinumab in postoperative Crohn's disease management: Evidence from a Chinese multicenter cohort. World J Gastroenterol 2026; 32(16): 116781
URL: https://www.wjgnet.com/1007-9327/full/v32/i16/116781.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i16.116781

Ma XZ, Han XZ, Zhang WY, Tian F, Zhou XC, Zhou LY, Teng YS, Lei L, Sheng JQ, Jin P, Zhao XM, Jia Y. Effectiveness of ustekinumab in postoperative Crohn's disease management: Evidence from a Chinese multicenter cohort. World J Gastroenterol 2026; 32(16): 116781 [DOI: 10.3748/wjg.v32.i16.116781]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.